Jordan’s Hikma Continues Buying Spree In MENA With Egypt Acquisition
This article was originally published in PharmAsia News
Executive Summary
Hikma will acquire Egypt’s EPCI as part of its strategy to grow in the Middle East and North Africa region. It has its sites on Turkey, but says acquisition targets are too pricey for now.
You may also be interested in...
Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm
Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.
A Bright Moment At Last In Turkish Medtech Debt Payments Saga
Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.